SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:lu ;pers:(Dillner Joakim)"

Sökning: LAR1:lu > Dillner Joakim

  • Resultat 1-10 av 42
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Andrae, Bengt, et al. (författare)
  • Screening-preventable cervical cancer risks evidence from a nationwide audit in Sweden.
  • 2008
  • Ingår i: J Natl Cancer Inst. - 1460-2105. ; 100:9, s. 622-9
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The effectiveness of cervical cancer screening programs differs widely in different populations. The reasons for these differences are unclear. Routine and comprehensive audits have been proposed as an ethically required component of screening. We performed a nationwide audit of the effectiveness of the Swedish cervical cancer screening program.Methods: We identified all invasive cervical cancer cases that were diagnosed in Sweden from January 1, 1999, through December 31, 2001, and had been reported to the Swedish Cancer Registry (n = 1230 cases). We verified the diagnoses by histopathologic rereview and matched each case subject to five (population-based) age-matched control subjects who were identified from the National Population Register. The Pap smear screening histories for case and control subjects were reviewed for a 6-year period using the National Cervical Cancer Screening Register, which contains data on essentially all relevant cytological and histological diagnoses in Sweden. Odds ratios (ORs), and their 95% confidence intervals (CIs), of cervical cancer according to screening history were calculated in conditional logistic regression models. All statistical tests were two-sided.Results: Women who had not had a Pap smear within the recommended screening interval had higher risk of cervical cancer than women who had been screened (OR = 2.52, 95% CI = 2.19 to 2.91). This risk was similarly increased for all age groups (Phomogeneity = .96). The risk for nonsquamous cell cervical cancers (OR = 1.59, 95% CI = 1.20 to 2.11) was also increased. Women who had not had a Pap smear within the recommended screening interval had a particularly high risk of advanced cancers (OR = 4.82, 95% CI = 3.61 to 6.44). Among women who had been screened within the recommended interval, those with abnormal Pap smears had a higher risk of cervical cancer than those with normal smears (OR = 7.55, 95% CI = 5.88 to 9.69) and constituted 11.5% of all women with cervical cancer.Conclusions: Nonadherence to screening intervals was the major reason for cervical cancer morbidity. The screening program was equally effective for women of all ages and was also effective against nonsquamous cancers.
2.
  • Appleby, P, et al. (författare)
  • Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies
  • 2007
  • Ingår i: The Lancet. - Elsevier Limited. - 1474-547X. ; 370:9599, s. 1609-1621
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Combined oral contraceptives are classified by the International Agency for Research on Cancer as a cause of cervical cancer. As the incidence of cervical cancer increases with age, the public-health implications of this association depend largely on the persistence of effects long after use of oral contraceptives has ceased. Information from 24 studies worldwide is pooled here to investigate the association between cervical carcinoma and pattern of oral contraceptive use. Methods Individual data for 16 573 women with cervical cancer and 35 509 without cervical cancer were reanalysed centrally. Relative risks of cervical cancer were estimated by conditional logistic regression, stratifying by study, age, number of sexual partners, age at first intercourse, parity, smoking, and screening. Findings Among current users of oral contraceptives the risk of invasive cervical cancer increased with increasing duration of use (relative risk for 5 or more years' use versus never use, 1-90 [95% Cl 1-69-2-13]). The risk declined after use ceased, and by 10 or more years had returned to that of never users. A similar pattern of risk was seen both for invasive and in-situ cancer, and in women who tested positive for high-risk human papillornavirus. Relative risk did not vary substantially between women with different characteristics. Interpretation The relative risk of cervical cancer is increased in current users of oral contraceptives and declines after use ceases. 10 years' use of oral contraceptives from around age 20 to 30 years is estimated to increase the cumulative incidence of invasive cervical cancer by age 50 from 7.3 to 8.3 per 1000 in less developed countries and from 3.8 to 4.5 per 1000 in more developed countries.
  •  
3.
  • Arbyn, M, et al. (författare)
  • Methods for screening and diagnosis
  • 2007
  • Ingår i: 2nd edition of the EU Guidelines for cervical cancer screening. - European Commission. - 978-92-79-07698-5 ; s. 69-141
  • Bokkapitel (övrigt vetenskapligt)
4.
  • Arbyn, Marc, et al. (författare)
  • Review of current knowledge on HPV vaccination: An Appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
  • 2007
  • Ingår i: Journal of Clinical Virology. - Elsevier. - 1386-6532. ; 38:3, s. 189-197
  • Forskningsöversikt (refereegranskat)abstract
    • The recognition of a strong etiological relationship between infection with high-risk human papillomavirusses and cervical cancer has prompted research to develop and evaluate prophylactic and therapeutic vaccines. One prophylactic quadrivalent vaccine using L1 virus-like particles (VLP) of HPV 6, 11, 16 and 18 is available on the European market since the end of 2006 and it is expected that a second bivalent vaccine containing VLPs of HPV 16 and HPV 18 will become available in 2007. Each year, HPV 16 and HPV 18 cause approximately 43,000 cases of cervical cancer in the European continent. Results from the phase-IIb and III trials published thus far indicate that the L1 VLP HPV vaccine is safe and well-tolerated. It offers HPV-naive women a very high level of protection against HPV persistent infection and cervical intra-epithelial lesions associated with the types included in the vaccine. HPV vaccination should be offered to girls before onset of sexual activity. While prophylactic vaccination is likely to provide important future health gains, cervical screening will need to be continued for the whole generation of women that is already infected with the HPV types included in the vaccine. Phase IV studies are needed to demonstrate protection against cervical cancer and to verify duration of protection, occurrence of replacement by non-vaccine types and to define future policies for screening of vaccinated cohorts. The European Guidelines on Quality Assurance for Cervical Cancer Screening provides guidance for secondary prevention by detection and management of precursors lesions of the cervix. The purpose of the appendix on vaccination is to present Current knowledge. Developing guidelines for future use of HPV vaccines in Europe, is the object of a new grant offered by the European Commission. (C) 2006 Elsevier B.V. All rights reserved.
  •  
5.
  • Arbyn, Marc, et al. (författare)
  • Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate
  • 2009
  • Ingår i: Journal of Cellular and Molecular Medicine. - Wiley-Blackwell. - 1582-1838. ; 13:4, s. 648-659
  • Forskningsöversikt (refereegranskat)abstract
    • Introduction Methods Results Discussion Conclusion Consistent evidence underlines the utility of human papillomavirus (HPV) DNA testing in the management of women with equivocal cervical cytological abnormalities, but not in case of low-grade lesions. We performed a meta-analysis including studies where the high-risk probe of the Hybrid Capture-II is used to triage these two cytological categories. The triage test-positivity rate reflects the colposcopy referral workload.Data were pooled on the HPV test positivity rate in women with atypical squamous cells of undetermined significance (ASCUS/ASC-US) or low-grade squamous intraepithelial lesions (LSIL), derived from different cytological classification systems. The meta-analysis was restricted to studies, published between 1991 and 2007. A random-effect model was applied for meta-analytical pooling and the influence of covariates on the HPV positivity rate was analyzed by meta-regression. The variation by age was assessed within individual studies since age strata were not defined uniformly. On an average, 43% (95% CI: 40-46%) of women with ASCUS/ASC-US were high-risk HPV positive (range 23-74%). In women with LSIL, the pooled positivity rate was 76% (95% CI: 71-81%; range 55-89%). In spite of considerable inter-study heterogeneity, the difference in HPV positivity between the two triage groups was large and highly significant: 32% (95% CI: 27-38%). HPV rates dropped tremendously as age and cutoffs of test positivity increased. Other factors (cytological classification system, country, continent, collection method and year of publication) had no statistically significant impact, except in LSIL triage where HPV positivity was significantly lower in European compared to American studies. Women with LSIL, especially younger women, have high HPV positivity rates suggesting limited utility of reflex HPV triaging these cases. Research is needed to identify more specific methods to triage women with low-grade squamous cervical lesions.
  •  
6.
  • Bistoletti, P, et al. (författare)
  • Screening for cervixcancer kan vara kostnadseffektiv. Kombinationen cellprov och HPV-test skulle ge ytterligare vinster.
  • 2005
  • Ingår i: Läkartidningen. - Sveriges Läkarförbund. - 0023-7205. ; 102:24-25, s. 1874-1879
  • Tidskriftsartikel (refereegranskat)abstract
    • En hälsoekonomisk utvärdering av cellprovsscreening för cervixcancer har saknats vad gäller svenska förhållanden. I en modellstudie jämfördes effekter av och kostnader för gynekologisk cellprovskontroll med och utan tillägg av test för humant papillomvirus (HPV). Med cellprovsscreening i åldern 32–60 år vart tredje till vart femte år minskar risken att insjukna i invasiv cervixcancer med 88 procent, och sjukvårdens kostnader halveras jämfört med att inte screena. Med tillägg av ett eller två HPV-test vid 32 års ålder och oförändrad screeningpolicy ökar kostnaderna, och inga hälsovinster kan påvisas. En screeningstrategi med cellprov i kombination med HPV-test vid enbart tre tillfällen i livet – vid 32, 41 och 50 års ålder – kostar mindre och ger, enligt modellen, hälsovinster jämfört med enbart cellprovsscreening i åldern 32–60 år.
7.
  • Brown, Darron R., et al. (författare)
  • The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
  • 2009
  • Ingår i: Journal Of Infectious Diseases. - University of Chicago Press. - 0022-1899. ; 199:7, s. 926-935
  • Konferensbidrag (refereegranskat)abstract
    • Background. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotying was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of >= 6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. Results. Vaccination reduced the incidence of HPV-31/45 infection by 40.3% (95% confidence interval [CI], 13.9% to 59.0%) and of CIN1-3/AIS by 43.6% (95% CI, 12.9% to 64.1%), respectively. The reduction in HPV-31/33/45/52/58 infection and CIN1-3/AIS was 25.0% (95% CI, 5.0% to 40.9%) and 29.2% (95% CI, 8.3% to 45.5%), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5% (95% CI, 6.0% to 51.9%). Reductions were most notable for HPV-31. Conclusions. HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for similar to 20% of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type.
  •  
8.
  • Bzhalava, D, et al. (författare)
  • Phylogenetically diverse TT virus viremia among pregnant women
  • 2012
  • Ingår i: Virology. - Elsevier. - 1096-0341. ; 432:2, s. 427-434
  • Tidskriftsartikel (refereegranskat)abstract
    • Infections during pregnancy have been suggested to be involved in childhood leukemias. We used high-throughput sequencing to describe the viruses most readily detectable in serum samples of pregnant women. Serum DNA of 112 mothers to leukemic children was amplified using whole genome amplification. Sequencing identified one TT virus (TTV) isolate belonging to a known type and two putatively new TTVs. For 22 mothers, we also performed ITV amplification by general primer PCR before sequencing. This detected 39 TTVs, two of which were identical to the Tilts found after whole genome amplification. Altogether, we found 40 TTV isolates, 29 of which were putatively new types (similarities ranging from 89% to 69%). In conclusion, high throughput sequencing is useful to describe the known or unknown viruses that are present in serum samples of pregnant women. (C) 2012 Elsevier Inc. All rights reserved.
  •  
9.
  • Cubilla, A L, et al. (författare)
  • Malignant epithelial tumors
  • 2004
  • Ingår i: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours. - IARC Press. - 9283224124 ; s. 281-281
  • Bokkapitel (övrigt vetenskapligt)
10.
  • Davies, P, et al. (författare)
  • A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening
  • 2006
  • Ingår i: International Journal of Cancer. - John Wiley & Sons. - 0020-7136. ; 118:4, s. 791-796
  • Forskningsöversikt (refereegranskat)abstract
    • Cervical cancer remains a significant public health concern, both at a global and a European level. A number of new technologies such as diagnostic tests for human papillomavirus (HPV) have a potential to assist with the reduction of this disease. However, both the efficacy and the cost-effectiveness of these new technologies must be established in properly designed trials before they can be implemented within national public health programs. Our study reviews the randomized controlled trials that are currently being conducted in Europe to establish the performance of HPV testing as a primary cervical cancer screening test. (c) 2005 Wiley-Liss, Inc.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 42
 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy